Ticker > Company >

Aurobindo Pharma share price

Aurobindo Pharma Ltd.

NSE: AUROPHARMA BSE: 524804 SECTOR: Pharmaceuticals & Drugs  223k   1k   277

1255.00
-7.40 (-0.59%)
BSE: Today, 04:00 PM

Price Summary

Today's High

₹ 1276.95

Today's Low

₹ 1242.3

52 Week High

₹ 1592.55

52 Week Low

₹ 959.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

72890.6 Cr.

Enterprise Value

75614.1 Cr.

No. of Shares

58.08 Cr.

P/E

35.23

P/B

3.71

Face Value

₹ 1

Div. Yield

0.36 %

Book Value (TTM)

₹  338.43

CASH

94.34 Cr.

DEBT

2817.84 Cr.

Promoter Holding

51.82 %

EPS (TTM)

₹  35.62

Sales Growth

25.88%

ROE

10.06 %

ROCE

11.56%

Profit Growth

52.97 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Aurobindo Pharma Ltd.

Molnaflu Imdur Betaloc Seloken Ramace Plendil RHINOCORT Prostodin MERONEM XyloCaine SensorCaine Iressa Casodex CRESTOR

Index Presence

The company is present in 34 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year25.88%
3 Year-12.38%
5 Year-2.78%

Profit Growth

1 Year59.25%
3 Year-14.38%
5 Year5.02%

ROE%

1 Year10.06%
3 Year8.65%
5 Year12.56%

ROCE %

1 Year11.56%
3 Year9.46%
5 Year13.48%

Debt/Equity

0.1429

Price to Cash Flow

42.51

Interest Cover Ratio

14.1595

CFO/PAT (5 Yr. Avg.)

1.29903919672632

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 51.82 20.39
Jun 2024 51.80 20.88
Mar 2024 51.83 20.86
Dec 2023 51.83 18.90
Sep 2023 51.83 19.56
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 1324.73 Cr.
  • Company has a healthy Interest coverage ratio of 14.1595.
  • Company’s PEG ratio is 0.665140270761791.
  • The company has a good cash flow management; CFO/PAT stands at 1.29903919672632.

 Limitations

  • The company has shown a poor profit growth of -15.1725071744374% for the Past 3 years.
  • The company has shown a poor revenue growth of -12.3762164630377% for the Past 3 years.
  • Promoter pledging is high as 20.39%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 2668.76 2692.03 2894.03 2460.09 2824.59
Total Expenditure 2123.58 2210.34 2119.24 1961.16 2103.71
Operating Profit 545.18 481.69 774.79 498.93 720.88
Other Income 67.08 331.13 122.97 65.32 122.66
Interest 36.69 61.25 53.07 51.13 51.63
Depreciation 65.79 64.35 64.81 66.88 68.16
Exceptional Items 0 0 0 0 0
Profit Before Tax 509.78 687.22 779.88 446.24 723.75
Tax 130.13 63.44 201.21 117.2 186.22
Profit After Tax 379.65 623.78 578.67 329.04 537.53
Adjusted EPS (Rs) 6.48 10.65 9.88 5.62 9.26

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 13370.77 15823.68 11287.14 8457 10645.64
Total Expenditure 10672.9 11703.85 9831.6 6952.09 8421.6
Operating Profit 2697.87 4119.83 1455.54 1504.91 2224.04
Other Income 388.79 589.86 688.85 443.92 616.06
Interest 243.28 28.68 16.94 74.58 182.6
Depreciation 473.33 488 415.26 243.26 254.58
Exceptional Items 0 0 -74.71 0 0
Profit Before Tax 2370.05 4193.01 1637.48 1630.99 2402.92
Tax 493.17 1080.1 182.77 388.82 502.82
Net Profit 1876.88 3112.91 1454.71 1227.11 1954.14
Adjusted EPS (Rs.) 32.03 53.13 24.83 21.2 32.43

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 58.59 58.59 58.59 58.59 58.59
Total Reserves 12993.91 15866.02 17058.75 17975.44 19664.23
Borrowings 0 0 0 0 0
Other N/C liabilities 138.86 1412.13 4566.44 3138.49 3399.83
Current liabilities 6372.25 6756.58 4180.97 6993.24 5746.81
Total Liabilities 19563.61 24093.32 25864.75 28165.76 28869.46
Assets
Net Block 4417.8 4472.07 3585.83 3687.5 2419.13
Capital WIP 814.85 719.02 225.15 239.09 132.68
Intangible WIP 0 15.87 0 0 0
Investments 2527.39 4880.89 6584.35 8105.36 13393.43
Loans & Advances 444.9 1610.41 5605.43 5800.45 5012.1
Other N/C Assets 70.37 59.05 28.88 53.78 170.92
Current Assets 11288.3 12336.01 9835.11 10279.58 7741.2
Total Assets 19563.61 24093.32 25864.75 28165.76 28869.46
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 2370.05 4193.01 1637.48 1611.23 2475.41
Adjustment 414.2 53.15 -30.65 175.2 69.61
Changes in Assets & Liabilities -204.18 -624.78 2811.95 330.37 -228.04
Tax Paid -378.69 -626.85 -692.07 -300.63 -602.18
Operating Cash Flow 2201.38 2994.53 3726.71 1816.17 1714.8
Investing Cash Flow -948.08 -2650.24 -1614.54 -3229.65 -151.58
Financing Cash Flow -1254.65 -28.06 -2447.54 1719.48 -1837.03
Net Cash Flow -1.35 316.23 -335.37 306 -273.81

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 51.83 51.83 51.83 51.80 51.82
axis clinicals limited 0.11 0.11 0.11 0.11 0.11
axis clinicals limited, t... 2.85 2.85 2.85 2.85 2.85
k spoorthi - - - - 1.19
k nityananda reddy 4.33 4.33 4.33 4.33 4.37
k rajeswari - - - - 0.31
kirthi reddy kambam 3.49 3.49 3.49 3.46 3.45
m sivakumaran 2.47 2.47 2.47 2.47 2.47
m sumanth kumar reddy 0.27 0.27 0.27 0.27 0.27
prasada reddy kambham 0.05 0.05 0.05 0.05 0.05
rpr sons advisors private... 33.51 33.51 33.51 33.51 33.50
suneela rani penaka 0.02 0.02 0.02 0.02 0.02
trident chemphar limited 0.13 0.13 0.13 0.13 0.13
venkata ramprasad reddy p... 3.07 3.07 3.07 3.07 3.07
kambam spoorthi 1.19 1.19 1.19 1.19 -
rajeshwari kambam 0.31 0.31 0.31 0.31 -
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 48.17 48.17 48.17 48.20 48.18
hdfc large and mid cap fu... - - - - 4.42
icici prudential manufact... - - - - 3.17
investor education and pr... - 0.14 - 0.14 0.15
life insurance corporatio... 5.43 3.81 3.38 2.78 2.08
mirae asset nifty midcap ... - - - - 2.34
nps trust- a/c icici prud... - - - - 1.57
quant mutual fund - quant... - - - 3.27 3.60
hdfc mutual fund-hdfc arb... - - - 4.34 -
icici prudential regular ... - - - 4.20 -
mirae asset nifty 200 alp... - - - 2.69 -
hdfc mutual fund - - 3.78 - -
icici prudential mutual f... - - 3.60 - -
investor education and pr... 0.14 - 0.14 - -
mirae asset large cap fun... - - 2.84 - -
quant mutual fund - - 2.54 - -
bnp paribas financial mar... - 1.62 - - -
hdfc mutual fund - hdfc s... 3.65 4.40 - - -
icici prudential midcap f... - 1.18 - - -
mirae asset elss tax save... - 1.78 - - -
quant mutual fund-quant e... - 2.20 - - -
bnp paribas arbitrage 1.41 - - - -
mirae asset equity saving... 1.65 - - - -
quant mutual fund-quant t... 1.80 - - - -

Ratings & Research Reports

Company Presentations

Company News

Aurobindo Pharma’s arm enters into agreement with global pharma major 25 Nov, 9:59 AM Aurobindo Pharma informs about company updates 23 Nov, 3:34 PM Aurobindo Pharma informs about investor meet 21 Nov, 5:34 PM Aurobindo Pharma informs about earnings call transcript 18 Nov, 4:30 PM Aurobindo Pharma’s arm gets GMP certificate of compliance for Hyderabad facility 13 Nov, 10:59 AM Aurobindo Pharma informs about press release 11 Nov, 2:55 PM Aurobindo Pharma’s Q2FY25 consolidated net profit rises by 9% 11 Nov, 11:26 AM Aurobindo Pharma - Quaterly Results 9 Nov, 7:13 PM Aurobindo Pharma - Quaterly Results 9 Nov, 7:13 PM Aurobindo Pharma - Quaterly Results 9 Nov, 7:13 PM Aurobindo Pharma completes acquisition of balance 49% stake of GLS Pharma 28 Oct, 10:51 AM Aurobindo Pharma’s arm to sell 50% shares in Novagen 5 Oct, 12:01 PM Aurobindo Pharma informs about disclosure 5 Oct, 10:31 AM Aurobindo Pharma gets USFDA’s final approval for Cephalexin Tablets 1 Oct, 4:25 PM USFDA completes inspection at API manufacturing facility of Aurobindo Pharma’s arm 30 Sep, 6:26 PM Aurobindo Pharma inks pact to acquire balance 49% stake in GLS Pharma 18 Sep, 5:15 PM Aurobindo Pharma informs about disclosure 18 Sep, 12:11 PM Aurobindo Pharma’s arm gets EIR for Andhra Pradesh facility 18 Sep, 11:58 AM Aurobindo Pharma informs about press release 11 Sep, 3:28 PM Aurobindo Pharma informs about analyst meet 28 Aug, 3:11 PM Aurobindo Pharma’s unit recalling products in US market over manufacturing issues 27 Aug, 12:24 PM USFDA pulls up Aurobindo Pharma's arm for manufacturing lapses at Telangana-based plant 26 Aug, 11:43 AM Aurobindo Pharma informs about press release 21 Aug, 3:38 PM Aurobindo Pharma to commence production in China facility 19 Aug, 2:26 PM Aurobindo Pharma informs about disclosure 16 Aug, 11:50 AM Aurobindo Pharma’s arm gets warning letter from USFDA for Unit-III 16 Aug, 11:41 AM Aurobindo Pharma informs about investor meeting 13 Aug, 12:36 PM Aurobindo Pharma informs about newspaper publication 12 Aug, 5:24 PM Aurobindo Pharma reports strong Q1 numbers; consolidated net profit surges 61% 12 Aug, 11:08 AM Aurobindo Pharma - Quaterly Results 10 Aug, 6:27 PM Aurobindo Pharma - Quaterly Results 10 Aug, 6:27 PM Aurobindo Pharma - Quaterly Results 10 Aug, 6:27 PM Aurobindo Pharma secures USFDA’s approval for Estradiol Vaginal Inserts 7 Aug, 12:30 PM Aurobindo Pharma’s arm gets 'Official Action Indicated' classification for Bhiwadi facility 6 Aug, 11:17 AM Aurobindo Pharma informs about earnings call 5 Aug, 12:09 PM Aurobindo Pharma informs about newspaper publication 31 Jul, 3:17 PM Aurobindo Pharma informs about board meeting 31 Jul, 12:04 PM Aurobindo Pharma’s step-down arm acquires entire stake in Ace Laboratories 29 Jun, 2:10 PM Aurobindo Pharma’s arm step-down gets Establishment Inspection Report for Telangana injectable facility 27 Jun, 2:56 PM Aurobindo Pharma informs about loss of shares certificate 12 Jun, 11:51 AM Aurobindo Pharma informs about analyst meet 6 Jun, 12:55 PM Aurobindo Pharma’s arm inks pact with MSD 3 Jun, 4:30 PM Aurobindo Pharma informs about newspaper publication 27 May, 12:56 PM Aurobindo Pharma reports 79% rise in Q4 consolidated net profit 27 May, 11:22 AM Aurobindo Pharma’s arm’s manufacturing unit gets 'official action indicated' status by USFDA 27 May, 10:00 AM Aurobindo Pharma - Quaterly Results 25 May, 7:01 PM Aurobindo Pharma - Quaterly Results 25 May, 7:01 PM Aurobindo Pharma - Quaterly Results 25 May, 7:01 PM USFDA concludes inspection at Unit-VII of Aurobindo Pharma’s arm in Andhra Pradesh 10 May, 5:41 PM USFDA concludes inspection at Unit-II of Aurobindo Pharma’s arm in Rajasthan 3 May, 6:02 PM

Aurobindo Pharma Stock Price Analysis and Quick Research Report. Is Aurobindo Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Aurobindo Pharma and its performance over the period of time. Aurobindo Pharma stock price today is Rs 1254.75.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Aurobindo Pharma cash from the operating activity was Rs 1714.8 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Aurobindo Pharma has a Debt to Equity ratio of 0.1429 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Aurobindo Pharma , the EPS growth was 52.9656 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Aurobindo Pharma has OPM of 20.8915574826877 % which is a good sign for profitability.
     
  • ROE: Aurobindo Pharma have a average ROE of 10.0649 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Aurobindo Pharma is Rs 1254.75. One can use valuation calculators of ticker to know if Aurobindo Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Aurobindo Pharma
X